Need for publication of all studies testing the SphygmoCor device  by Lehmann, Eldon D.
Kidney International, Vol. 60 (2001), pp. 801–803
LETTERS TO THE EDITOR
Imperial College of Science Technology and Medicine, Royal Brompton
Hospital, Sydney Street, London SW3 6NP, United Kingdom.Need for publication
E-mail: info-www@2aida.org
of all studies testing
REFERENCES
the SphygmoCor device 1. Goldsmith DJA: Cited “validation” references for the SphygmoCor
device. Reply from the author [letter]. Kidney Int 59:1597–1598, 2001
2. Lehmann ED: Aortic pulse-wave velocity versus pulse pressure and
pulse-wave analysis [letter]. Lancet 355:412, 2000To the Editor: I was disappointed to read Dr. Gold-
3. Lehmann ED: Where is the evidence that radial artery tonometrysmith’s reply [1] regarding the citation of unrelated arti- can be used with a generalised transfer function to accurately and
cles as “validation” references for the use of the Sphyg- non-invasively predict central aortic blood pressure? [letter]. J Hum
Hypertens 15:145–146, 2001moCor blood pressure device (PWW Medical, Inc.,
Sydney, Australia). In his “response,” Dr. Goldsmith
accuses me of censuring others. This is incorrect.
I was invited to Sydney by the main proponent of the Reply from the author
SphygoCor device to undertake research in 1995 and I understand that Dr. Lehmann has significant reserva-
again in 1996 [abstract; Plunkett BT, et al, Z Kardiol 85 tions about the validation of the SphygmoCor apparatus.
(Suppl 3):136, 1996)]. While there, I observed actual I do not share them. Let history (that is, future valida-
intra-aortic blood pressures being recorded during car- tions, which I call for as fervently as he does) be the
diac catherization in 15 patients, simultaneously with judge.
noninvasive SphygmoCor device measurements. The lat-
ter method did not provide me with great confidence in David J.A. Goldsmith, for the authors
the use of the device for predicting central aortic blood London, England, United Kingdom
pressure because the errors associated with the Sphyg-
Correspondence to David J.A. Goldsmith, M.A., F.R.C.P., RenalmoCor device were substantial. Unit, 4th Floor Thomas Guy House, Guy’s Hospital, St. Thomas Street,
Furthermore, during my second trip, I was made aware London, SEI 9RT England, United Kingdom.
of details of two additional studies that had also sought
to test the SphygmoCor device. Both used invasive intra-
arterial blood pressure data to recalibrate the noninva-
sively recorded SphygmoCor waveforms. Both studies Elevated blood pressure
demonstrated that the SphygmoCor device had substan-
tial and increasing errors with increasing blood pressure predicts risk of acute rejection
values. Therefore, the device appeared least accurate in
hypertensive patients. in renal allograft recipients
None of these studies has been published, which is
the reason I have felt a responsibility to the scientific
To the Editor: The findings in the paper by Cosio et alcommunity to generate some discussion about the inac-
[1] are reminiscent of our data on the transmission ofcuracies inherent in this approach [2, 3], especially since
familial hypertension via the donor’s kidney and its rela-some researchers have begun to apply the methodology
tionship with a higher vulnerability to kidney damage.with no validation data to support its use.
While Cosio et al showed that in renal transplantedDr. Goldsmith will surely join me in calling for data
patients arterial hypertension identifies patients at higherfrom all these studies, which date back to 1995 and 1996,
risk of acute rejections independently from renal func-to be made public so that researchers can draw their
tion and other variables known to be associated withown conclusions about the accuracy of the technique.
greater occurrence of acute rejections, in a similar study
Eldon D. Lehmann equally restricted to the first year after transplantation,
London, England, United Kingdom we showed that familiality for hypertension in the donor
not only determined a higher requirement for antihyper-Correspondence to Dr. Eldon D. Lehmann, M.B., B.S., B.Sc., De-
tensive therapy in the recipient [2], but also a greaterpartment of Imaging (MR Unit), National Heart and Lung Institute,
kidney involvement during an acute rejection episode
(as judged by blood pressure level and serum creatinine
increase), without increasing the number of acute rejec- 2001 by the International Society of Nephrology
801
